1 not yet recruiting, 1 recruiting, 1 terminated, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Malignant Mesothelioma (MM): new trials by email Literature Review of Malignant Mesothelioma (MM) trials Research Report on Malignant Mesothelioma (MM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma alrizomadlin - Mesothelioma, Malignant Mesothelioma (MM) | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-03-16 | 2026-03-17 | |
| Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors TYK-01054 - Solid Tumor Malignancies, Malignant Mesothelioma (MM) | Phase 1 / Phase 2 | Not yet recruiting | TYK Medicines, Inc | 219 | 2026-01-01 | 2025-12-22 |
| Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma Decitabine/cedazuridine - Mesothelioma, Malignant Mesothelioma (MM) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 15 | 2024-01-31 | 2026-10-16 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
Mesothelioma, Malignant (4) · Mesothelioma (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Glioblastoma (1) · Nasopharyngeal Carcinoma (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Adenoma (4) · Lung Diseases (4) · Lung Neoplasms (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Mesothelial (4) · Pleural Neoplasms (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Mesothelioma (2) · Adenocarcinoma (1) · Adnexal Diseases (1)
decitabine and cedazuridine drug combination (1)
National Cancer Institute (NCI) (2) · TYK Medicines, Inc (1) · Telix Pharmaceuticals (Innovations) Pty Ltd (1)
United States (3) · China (1)